The NADPH oxidase system is an enzymatic complex that generates superoxide. It is formed by membrane components, gp91-phox and p22-phox subunits (flavocytochrome b558), and cytoplasmic components (p47-phox, p67-phox and p40-phox). Defects in the expression of these components lead to Chronic Granulomatous Disease (CGD), a severe primary immunodeficiency characterized by the early onset of severe and recurrent infections. To date, allogeneic transplantation of hematopoietic stem cells has been the treatment of choice for patients affected by this disease, however, it is only available to a third of the patients due to HLA (human leukocyte antigen) compatibility issues. Gene therapy can fill this treatment gap once primary patient cells can be genetically corrected and transplanted back to the same donor, with the possibility of cure. Gene therapy protocols for CGD based on gammaretroviral vectors have not shown good results. In this context, pre-clinical trials have shown efficiency in correcting the expression of NADPH oxidase components by the substitution of gammaretroviral vectors by lentiviral vectors. Considering the importance of developing an effective gene therapy for patients with CGD and the promising results found in the literature through the use of lentiviral vectors, in the present BEPE project we will test the efficiency of a new lentiviral vector for correction of the expression of the NADPH oxidase p47-phox component based on the chimeric vector pCCLchim, which is well characterized by Santilli and colleagues (2011).
News published in Agência FAPESP Newsletter about the scholarship: